ARVO celebrates 75 years of research, vision
April 15th 2003Fort Lauderdale, FL-The Association for Research in Vision and Ophthalmology (ARVO) turns 75 years this year. To commemorate this major milestone, several special events are planned during the annual meeting from May 4 to 8 in Fort Lauderdale, FL.
Microbursts of ultrasound increase safety, efficiency
April 15th 2003Orlando-WhiteStar, a power control upgrade for the Sovereign system (AMO, Santa Ana, CA), maximizes the efficiency and safety of phacoemulsification for cataracts of any hardness, according to speakers at an American Academy of Ophthalmology an-nual meeting breakfast symposium sponsored by AMO.
IOL edge design directly affects ability to see at night
April 15th 2003Salt Lake City-Dysphotopsias, the unwant-ed optical images seen at night, pose an annoying and sometimes debilitating effect for cataract patients receiving IOLs with a truncated edge. To minimize these effects, efforts to modify the IOL edge have paid off, according to Randall J. Olson, MD.
Povidone-iodine considered best endophthalmitis prophylaxis
April 15th 2003Indianapolis-Preoperative povidone-iodine antisepsis showed the strongest support in the literature for preventing bacterial endophthalmitis in patients undergoing cataract surgery. However, that recommendation was judged to be only "moderately important" to clinical outcome, based on the quality of the available evidence. The review failed to find that any technique was crucial to clinical outcome, said Thomas A. Ciulla, MD.
Automated anterior lamellar keratoplasty offers advantages
April 15th 2003Forli, Italy-Automated anterior lamellar keratoplasty offers a number of advantages over other therapeutic approaches in the treatment of keratoconus, according to Massimo Busin, MD. Importantly, patients experience rapid visual recovery and achieve exceptionally good visual acuity (VA) results.
Monovision LASIK more predictable for myopic patients
April 15th 2003Little Silver, NJ-LASIK monovision is a viable choice for both myopia and hyperopia, but careful patient selection is crucial for best results, particularly among patients with hyperopia, said Daniel B. Goldberg, MD, FACS, Atlantic Laser Center, Little Silver, NJ.
Re-treatment after LASIK is no trivial matter
April 15th 2003Baltimore-Use caution when re-treating a patient who has had refractive surgery, advised Nada S. Jabbur, MD. Just as care should be taken in performing initial LASIK procedures, re-treatments require special care and should not be trivialized, according to Dr. Jabbur.
Antibiotic combats acute bacterial conjunctivitis
April 15th 2003Andover, MA-The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day of treatment and 90% by 7 to 9 days, according to a phase II clinical trial.
Patching, atropine offer similar benefits for moderate amblyopia
April 15th 2003Orlando-Children with moderate amblyopia may be successfully treated with patching or atropine drops, regardless of age less than 7 years or depth of amblyopia for the most common causes of amblyopia, according to Michael X. Repka, MD, at the American Academy of Ophthalmology annual meeting.
B&L wins extended range on laser; delays implant application
April 15th 2003Rochester, NY-On the same day Bausch & Lomb celebrated FDA approval of a larger treatment range for its Technolas 217A excimer laser system, it said it would delay a year before asking the FDA to approve its Retisert drug-delivery implant.
LASIK speculum helps maximize ocular surface exposure
April 15th 2003The Steinert II LASIK speculum (Rhein Medical) helps to increase ocular surface exposure for the positioning of a microkeratome, according to refractive and anterior segment surgeon Roger F. Steinert, MD, who was involved in its design.
Diffractive optic IOL provides good near, distance vision in all lighting conditions
April 1st 2003New Orleans-The AcrySof ReSTOR IOL (Alcon), with apodized diffractive optic technology, is providing good near vision and good distance vision under all lighting conditions, based on early results in U.S. clinical trials. In addition, the lens is producing few unwanted visual phenomena, according to Stephen Brint, MD.
Should a prostaglandin agent be used as initial monotherapy?
April 1st 2003Not long after topical timolol was introduced in 1978, it became one of the most widely prescribed glaucoma medications in the world. Although timolol is considered to be the most significant therapeutic advance in the medical treatment of glaucoma in the 20th century, the 1994 introduction of prostaglandin analogs for glaucoma treatment in Japan marked the end of timolol's domination.
Eyelid lesion management requires careful history, exam
April 1st 2003Baltimore-Ophthalmologists can be comfortable identifying and managing certain eyelid lesions in their offices if they pay attention to a few basic principles. A working knowledge of common benign and malignant lesions is the key to managing these lesions, according to Shannath L. Merbs, MD, PhD, who spoke at the Current Concepts in Ophthalmology meeting here.
OHTS identifies thinner corneas as risk for visual changes
April 1st 2003Omaha, NE-The Ocular Hypertension Treatment Study (OHTS) clearly demonstrat-ed that topical IOP-lowering medications can delay the onset of primary open-angle glaucoma. In addition, the OHTS study also revealed two very important secondary messages, which may be as important as the primary finding, according to M. Roy Wilson, MD.